RxDoctor Payments Data

Erin Schreier, DO

Family Medicine · Excelsior Springs, MONPI 1568480952

Payments from drug & device makers

$5,813in general payments, 2019–2025

Across 395 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$629
  • Pfizer$490
  • AstraZeneca$442
  • Novo Nordisk$357
  • Sunovion Pharmaceuticals Inc.$267
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,813 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$146,805
Medicare patients
353
Services billed
3,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide155$204,483
JardianceEmpagliflozin130$120,449
EliquisApixaban108$113,447
MounjaroTirzepatide57$75,546
OxycontinOxycodone Hcl12$58,815
VraylarCariprazine Hcl28$43,564
TrulicityDulaglutide18$32,235
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$29,148
MyrbetriqMirabegron48$28,079
Tresiba Flextouch U-200Insulin Degludec26$22,807
LinzessLinaclotide14$21,647
GemtesaVibegron21$21,433
JanuviaSitagliptin Phosphate25$21,295
RexultiBrexpiprazole27$19,514
XareltoRivaroxaban29$16,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$357$204,483155 claims
Boehringer IngelheimJardiance, Tradjenta$107$131,853142 claims
PfizerEliquis, Abrysvo$490$122,628146 claims
Lilly USA, LLCMounjaro, Trulicity$629$107,78075 claims
AbbVieVraylar, Linzess$1,433$65,21142 claims
GSKAnoro Ellipta, Breo Ellipta$132$37,92948 claims
Astellas Pharma US IncMyrbetriq$69$28,07948 claims
MerckJanuvia, Belsomra$94$27,22538 claims
Sumitomo Pharma America, Inc.Gemtesa$75$21,43321 claims
Otsuka America Pharmaceutical, Inc.Rexulti$103$19,51427 claims
Johnson & JohnsonXarelto$33$16,25029 claims
AstraZenecaFarxiga$442$12,08815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Excelsior Springs

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →